| Name | Life Science REIT |
|---|---|
| Epic | LABS |
| Isin | GB00BP5X4Q29 |
| Index | MID300 |
| Industry | Real Estate Investment Trusts |
| Latest share price | 37.50p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £131.25 | Debt ratio | n/a |
| Shares in issue | 350.00 | Debt-to-equity ratio | n/a |
| P/E ratio | 22.4 | Assets / equity ratio | n/a |
| Total dividends per share | 1.00p | Price to book value | n/a |
| Dividend yield | 2.6 | ROCE | -2.02 |
| Dividend cover | 1.7 | EPS growth | -10 |
| Earning per share | -4 | 52-week high / low | 32.80p / 48.60p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Interim | 2024-10-03 | 2024-10-31 | 1.00p |
| 2nd Interim | 2024-04-04 | 2024-05-13 | 1.00p |
| Interim | 2023-09-28 | 2023-10-31 | 1.00p |
| 2nd Interim | 2023-04-13 | 2023-05-15 | 3.00p |
| Interim | 2022-09-29 | 2022-10-31 | 1.00p |
| Company name | Life Science REIT |
|---|---|
| Address | Central Square, 29 Wellington Street, Leeds, United Kingdom, LS1 4DL |
| Telephone | +44 (0) 333 300 1950 |
| Website | http://www.lifesciencereit.co.uk/ |
| Director | Position |
|---|---|
| Mrs Claire Boyle (née Barnes) | Non-Executive Chairman |
| Mr Richard Howell | Senior Independent Director |
| Dr Sally Ann Forsyth | Independent Non-Executive Director |
| Mr Michael Taylor | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 389.05 | 389.71 | 394.12 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 4.2 | 6.66 | 7.66 |
| Cash and equivalents | 5.57 | 14.34 | 45.61 |
| Other current assets and asset held for resale | 2.38 | n/a | 0.43 |
| Total of all assets | 401.19 | 410.7 | 447.83 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 12.35 | 14.44 | 50.44 |
| Long term liabilities | 126.06 | 112.52 | 77.93 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 138.42 | 126.96 | 128.37 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 262.77 | 283.75 | 319.45 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 3.5 | 3.5 | 3.5 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -55.55 | -41.58 | -19.87 |
| Share premium account | n/a | n/a | n/a |
| Total equity | 262.77 | 283.75 | 319.45 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -7.79 | -14.59 | -26.94 |
| Pre-tax profit | -13.98 | -21.85 | -27.47 |